bluebird bio

BLUE NASDAQ
119.78
-2.92
-2.38%
Opening 15:07 06/18 EDT
Open
126.12
Prev Close
122.70
High
126.12
Low
118.10
Volume
731.23K
Avg Vol (3M)
466.55K
52 Week High
189.31
52 Week Low
87.49
% Turnover
1.33%
Market Cap
6.60B
1D
5D
1M
3M
1Y
5Y

Related

Webull offers bluebird bio BLUE stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company's clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD). Its programs in oncology focuses on developing T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies. bb2121, its lead product candidate in oncology, is a CAR T cell product candidate for the treatment of multiple myeloma. It also has discovery research programs utilizing megaTALs/homing endonuclease gene editing technologies for use across its pipeline.
MORE >

Recently

Name
Price
%Change